Evogene
NASDAQ:EVGNNess Ziona, Israel· Est.
AI‑driven small‑molecule design platform for pharma and ag‑chemicals.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
AI‑driven small‑molecule design platform for pharma and ag‑chemicals.
Small Molecule TherapeuticsAgricultural Crop Protection
Technology Platform
ChemPass AI™ is a proprietary generative AI engine that designs novel small molecules optimized across potency, safety, ADME, and synthetic feasibility parameters.
Opportunities
Scaling ChemPass AI™ across more pharma and ag‑tech collaborations can accelerate candidate generation and generate milestone‑based revenues.
Risk Factors
Reliance on AI prediction accuracy, regulatory acceptance of AI‑designed molecules, and intense competition from other AI drug‑design platforms pose significant risks.
Competitive Landscape
Key competitors include Insilico Medicine, Exscientia, Atomwise, and BenevolentAI; Evogene differentiates through its multi‑parameter optimization engine and strong focus on both pharma and agriculture.